Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34101
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPiperoglou, Michael-
dc.contributor.authorHopwood, Malcolm-
dc.contributor.authorNorman, Trevor R-
dc.date2023-
dc.date.accessioned2023-11-03T03:10:07Z-
dc.date.available2023-11-03T03:10:07Z-
dc.date.issued2023-11-
dc.identifier.citationJournal of Clinical Psychopharmacology 2023-11; 43(6)en_US
dc.identifier.issn1533-712X-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34101-
dc.description.abstractThe aim of the study is to examine the efficacy of omega-3 fatty acid as an adjunct to ongoing pharmacological treatments in patients with residual symptoms of depression and anxiety. This randomized, double-blind, placebo-controlled, cross-over trial was conducted at a single private practice site. Participants were drawn from patients attending the practice.Patients meeting criteria had a 4-week run-in period where they continued to receive their prescribed medications and omega-3 supplements. Depression and anxiety ratings were assessed at recruitment and completion of the run-in phase. Patients were randomized to receive an omega-3 supplement (Neurospark) or placebo once daily for 8 weeks then crossed over to the alternative treatment. At the end of the double-blind, cross-over phase patients received the supplement and were assessed after a 4-week run-out phase.Depression and anxiety symptoms were assessed using the Hamilton scales. Efficacy of treatment was assessed using a linear mixed model analysis with time, order of treatment, diagnosis, and their interaction as factors. Depression and anxiety scales were analyzed as independent measures. The study enrolled 47 patients (mean [SD] age, 46.1 [11.2] years; [59.6%] male). Depression scores did not significantly change across assessments ( P > 0.1); there was no effect of order of treatment ( P > 0.1) or an interaction between time, order of treatment, and psychiatric diagnosis ( P > 0.1). Anxiety scores were similarly unchanged across treatment visits and order of treatment, and there was no interaction between time, order of treatment, and psychiatric diagnosis. Omega-3 fatty acid supplementation did not significantly alter residual symptoms in this group of patients.en_US
dc.language.isoeng-
dc.titleAdjunctive Docosahexaenoic Acid in Residual Symptoms of Depression and Anxiety.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Clinical Psychopharmacologyen_US
dc.identifier.affiliationFrom the Epworth Hospital, Camberwell.en_US
dc.identifier.affiliationDepartment of Psychiatry, University of Melbourne, Melbourne.en_US
dc.identifier.affiliationPsychiatry (University of Melbourne)en_US
dc.identifier.doi10.1097/JCP.0000000000001767en_US
dc.type.contentTexten_US
dc.identifier.orcid0000000334011763en_US
dc.identifier.orcid0000-0001-6004-4521en_US
dc.identifier.orcid0000-0003-2903-7096en_US
dc.identifier.pubmedid37878482-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptPsychiatry (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Mar 3, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.